Lemaitre Vascular
Open
$108.24
Prev. Close
$108.23
High
$108.24
Low
$108.19
Market Snapshot
$2.43B
42.1
1.97
$219.86M
646
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company is headquartered in Burlington, Massachusetts and currently employs 646 full-time employees. The company went IPO on 2006-10-19. The firm develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. The company also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.
LeMaitre Vascular reported a 47% increase in operating income, boosting its share price to $112.40, highlighting strong financial performance in the vascular device industry.
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company is headquartered in Burlington, Massachusetts and currently employs 646 full-time employees. The company went IPO on 2006-10-19. The firm develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. The company also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.
Recently from Cashu
It seems there was a misunderstanding; there's no content provided for me to summarize. Please provide the specific text you'd like summarized, and I will assist you accordingly!
Please provide the specific text you would like summarized.
LeMaitre Vascular Reports Strong Growth and Commitment to Innovative Vascular Solutions
LeMaitre Vascular Reinforces Leadership in Innovative Vascular Solutions LeMaitre Vascular, a prominent player in the vascular device industry, consistently showcases its commitment to innovation and…
LeMaitre Vascular's Q4 Earnings Highlight Growth Driven by Innovation and Market Demand
LeMaitre Vascular's Q4 Performance: A Testament to Innovation and Market Demand LeMaitre Vascular (NASDAQ: LMAT) recently announces its Q4 earnings, showcasing a robust financial performance driven by…
Lemaitre Vascular: Leading Innovations in Vascular Surgery Solutions and Patient Care
Lemaitre Vascular's Advancements in Vascular Surgery Solutions Lemaitre Vascular, a prominent player in the vascular surgery market, continues to enhance its product offerings and expand its reach wit…